Cargando…
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
INTRODUCTION: Given the varying severity of coronavirus disease 2019 (COVID-19) and the rapid spread of Severe-Acute-Respiratory-Syndrome-Corona-Virus-2 (SARS-CoV-2), vaccine-mediated protection of particularly vulnerable individuals has gained increasing attention during the course of the pandemic....
Autores principales: | Räuber, Saskia, Willison, Alice, Korsen, Melanie, Kölsche, Tristan, Golombeck, Kristin S., Plaack, Benedikt, Schüller, Julia, Huntemann, Niklas, Rolfes, Leoni, Schroeter, Christina B., Nelke, Christopher, Regner-Nelke, Liesa, Förster, Moritz, Ringelstein, Marius, Barnett, Michael Harry, Hartung, Hans-Peter, Aktas, Orhan, Albrecht, Philipp, Ruck, Tobias, Melzer, Nico, Meuth, Sven G., Kremer, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822773/ https://www.ncbi.nlm.nih.gov/pubmed/36618356 http://dx.doi.org/10.3389/fimmu.2022.1037214 |
Ejemplares similares
-
Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022) -
Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
por: Pfeuffer, Steffen, et al.
Publicado: (2023) -
Enjoy Carefully: The Multifaceted Role of Vitamin E in Neuro-Nutrition
por: Regner-Nelke, Liesa, et al.
Publicado: (2021) -
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021) -
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2022)